Hasten Biopharma acquires commercial rights for Roche's Rocephin in China
Shanghai: Hasten Biopharmaceutic Co., Ltd (China) has announced that it has acquired the commercial rights in China for Rocephin from Swiss multinational healthcare company, Roche. Following the closing of the transaction earlier this year, there will be a transition period between Hasten and Roche.
Under the agreement, Hasten acquired Roche's China mainland rights for Rocephin, including the product's marketing authorization and certain intellectual property, including trademarks. As a critical care product, Rocephin is a broad-spectrum antibiotic with strong brand value.
Read also: Roche collaborates with Eli Lilly to enhance early diagnosis of Alzheimer's disease
Rocephin is a long-acting, broad spectrum cephalosporin antibiotic for parenteral use. It is approved for use in children and adults for many infections such as: sepsis; meningitis; abdominal infections; infections of the bones, joints, soft tissue or skin; renal or urinary tract infections; respiratory tract infections; ear, nose and throat infections; genital infections; disseminated Lyme borreliosis; and perioperative prophylaxis of infections.
"Hasten is committed to building a leading innovative medical and healthcare enterprise in China. The acquisition of Rocephin delivers strong commercial synergy with Hasten's current critical care portfolio in the Emergency Room, Intensive Care Unit, and Surgery departments, and positions us well to continue providing best-in-class treatments to benefit more patients," Summer Xia, CEO of Hasten Biopharma, said.
Hasten is an investment of CBC Group, Asia's healthcare-dedicated investment firm headquartered in Singapore, Hefei Industry Investment Group, and Feidong County of Hefei City.
Read also: Roche blood cancer drug Columvi gets EMA panel recommendation for EU approval
